The Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium is a group of scientists, clinicians, patients, and advocates working together to advance therapeutic development for amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders. Here, CReATe leaders share the history of the consortium, current research, and future plans.
Corey McMillan, PhD, is an associate professor of neurology at the University of Pennsylvania and principal investigator of the Penn Bioinformatics in Neurodegenerative Disease (BiND) Lab. He is also a member of the Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium. His research focuses on multimodal and bioinformatic approaches to improve our understanding of the biological basis of neurodegenerative conditions. Here, he shares his start in rare disease research, exciting discoveries, and future goals.
